05-217 | Anti-PI3 Kinase Antibody, p85, N-SH2,

05-217
200 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RWB, IPMCulture SupernatantMonoclonal Antibody
      Description
      Catalogue Number05-217
      Replaces04-403
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-PI3 Kinase Antibody, p85, N-SH2,
      Alternate Names
      • PI3-kinase p110 subunit alpha
      • PtdIns-3-kinase p110
      • phosphatidylinositol 3-kinase, catalytic
      • 110-KD
      • alpha
      • phosphatidylinositol 3-kinase, catalytic
      • alpha polypeptide
      • phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform
      • phosphoinositide-3-kinase, catalytic, alpha polypeptide
      Background InformationThe enzyme phosphatidylinositol 3 kinase (PI3 kinase) is a lipid kinase that is thought to phosphorylate second messengers in growth signalling pathways. PI3K exists as a heterodimer of catalytic 110 kDa (p110) and regulatory 85 kDa (p85, p50 or p55) subunits. The p85 unit consists of two closely related proteins: p85 alpha, which binds tightly to the catalytic subunit and p85 beta, a protein of unknown function. They share 62% amino acid sequence identity. p85 alpha lacks PI3 kinase activity, but may serve as regulator of the catalytic subunit, p110, by acting as the link between PI3K and the ligand activated receptor. Both isoforms bind to activated receptors and serve as tyrosine kinase substrates.
      References
      Product Information
      FormatCulture Supernatant
      Control
      • Positive Control Included: Non-Stim A431 Cell Lysate (12-301).
        Included Positive Antigen Control: Catalog #12-301, non-stimulated A431 cell lysate. Add 2.5 µL of 2-mercaptoethanol/100 µL of lysate and boil for 5 minutes to reduce the preparation. Load 20 µg of reduced lysate per lane for minigels.
      PresentationMouse monoclonal IgG in buffer containing culture supernatant fraction in frozen solution.
      Applications
      ApplicationAnti-PI3 Kinase Antibody, p85, N-SH2, is an antibody against PI3 Kinase for use in WB & IP.
      Key Applications
      • Western Blotting
      • Immunoprecipitation
      Application NotesImmunoprecipitation: Use 5 µL per sample.
      Biological Information
      ImmunogenGST fusion protein corresponding to N-Terminal SH2 region (amino acid residues 327-434) of rat phosphoinositide 3-Kinase.
      EpitopeN-terminus
      Cloneclone UB93-3
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      SpecificityRecognizes N-SH2 region of p85 alpha subunit of PI3 Kinase.
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Species Reactivity NoteHuman, rat; mouse; other species cross-reactivity is unknown.
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryPhosphatidylinositol 3-kinase phosphorylates the inositol ring of phosphatidylinositol at the 3-prime position. The enzyme comprises a 110 kD catalytic subunit and a regulatory subunit of either 85, 55, or 50 kD. This gene encodes the 85 kD regulatory subunit. Phosphatidylinositol 3-kinase plays an important role in the metabolic actions of insulin, and a mutation in this gene has been associated with insulin resistance. Alternative splicing of this gene results in three transcript variants encoding different isoforms.
      Gene Symbol
      • PIK3R1
      • GRB1
      • PI3K
      • p85-ALPHA
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P27986 # Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.
      SIZE: 724 amino acids; 83598 Da
      SUBUNIT: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunits. Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3 (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C- terminus of both proteins and leads to increased production of HIV. Interacts with HCV NS5A. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1.
      TISSUE SPECIFICITY: Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).
      DOMAIN: SwissProt: P27986 The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.
      PTM: Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.DISEASE:SwissProt: P27986 # Defects in PIK3R1 are a cause of severe insulin resistance.
      SIMILARITY: Belongs to the PI3K p85 subunit family. & Contains 1 Rho-GAP domain. & Contains 2 SH2 domains. & Contains 1 SH3 domain.
      Molecular Weight85 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceWestern blot Analysis: A 1:100-1:200 dilution of this antibody detected PI3-Kinase in RIPA lysates from human A431 carcinoma cells and previously from mouse 3T3/A31 fibroblasts.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at from date of receipt.
      Packaging Information
      Material Size200 µL
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SDS

      Title

      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 2144395 2144395
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 16041 16041
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 17887 17887
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 19051 19051
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 2031381 2031381
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 2243503 2243503
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 22814 22814
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 2318091 2318091
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 24122 24122
      Anti-PI3 Kinase, p85, N-SH2, clone UB93-3 - 31663 31663

      References

      Reference overviewApplicationPub Med ID
      PPARbeta activation induces rapid changes of both AMPK subunit expression and AMPK activation in mouse skeletal muscle.
      Lendoye, E; Sibille, B; Rousseau, AS; Murdaca, J; Grimaldi, PA; Lopez, P
      Molecular endocrinology (Baltimore, Md.)  25  1487-98  2011

      Show Abstract
      21798999 21798999
      Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes.
      Naïmi, M; Gautier, N; Chaussade, C; Valverde, AM; Accili, D; Van Obberghen, E
      Endocrinology  148  2424-34  2007

      Show Abstract
      17303659 17303659
      Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT.
      J M Vanderwinden, D Wang, N Paternotte, S Mignon, K Isozaki, C Erneux
      Cellular signalling  18  661-9  2006

      Show Abstract
      15990278 15990278
      The smaller isoforms of ankyrin 3 bind to the p85 subunit of phosphatidylinositol 3'-kinase and enhance platelet-derived growth factor receptor down-regulation.
      Ignatiuk, A; Quickfall, JP; Hawrysh, AD; Chamberlain, MD; Anderson, DH
      The Journal of biological chemistry  281  5956-64  2006

      Show Abstract
      Western Blotting16377635 16377635
      The p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the GTPase activity of Rab proteins.
      Chamberlain, MD; Berry, TR; Pastor, MC; Anderson, DH
      The Journal of biological chemistry  279  48607-14  2004

      Show Abstract
      Western Blotting15377662 15377662
      Role of IRS-3 in the insulin signaling of IRS-1-deficient brown adipocytes.
      Arribas, M; Valverde, AM; Benito, M
      The Journal of biological chemistry  278  45189-99  2003

      Show Abstract
      12944402 12944402
      Phosphatidylinositol 3-kinase interacts with the adaptor protein Dab1 in response to Reelin signaling and is required for normal cortical lamination.
      Bock, HH; Jossin, Y; Liu, P; Förster, E; May, P; Goffinet, AM; Herz, J
      The Journal of biological chemistry  278  38772-9  2003

      Show Abstract
      12882964 12882964
      Involvement of p85 in p53-dependent apoptotic response to oxidative stress
      Yin, Y., et al
      Nature, 391:707-10 (1998)  1998

      Immunoblotting (Western)9490416 9490416
      Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1
      Thomas, J. E., et al
      J Biol Chem, 271:28630-5 (1996)  1996

      Immunoblotting (Western), Immunoprecipitation8910495 8910495
      The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2.
      Platanias, L C, et al.
      J. Biol. Chem., 271: 278-82 (1996)  1996

      Show Abstract
      8550573 8550573

      FAQ

      QuestionAnswer
      What is the concentration of this antibody?We are not able to quantitate cultured supernatants.

      Related Products & Applications

      Included Positive Control

      Catalogue Number Description  
      12-301 Non-Stimulated A431 Cell Lysate Show Pricing & Availability

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies